CERo Therapeutics Holdings, Inc. Common Stock (CERO NASDAQ) stock market data APIs
$9.3107
-0.02(-0.2%)
as of July 3, 2025
Try our APIs with
free plan!
CERo Therapeutics Holdings, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Prev. Close
9.3107
Open
9.2917
High
9.5316
Low
9.2621
52 wk Range
6.71-896
Market Cap
4 786 K
Shares Outstanding
51 354 K
EPS
-31.8
Beta
-0.437
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CERo Therapeutics Holdings, Inc. Common Stock data using free add-ons & libraries
Get CERo Therapeutics Holdings, Inc. Common Stock Fundamental Data
CERo Therapeutics Holdings, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get CERo Therapeutics Holdings, Inc. Common Stock Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: 2025-05-15
- EPS/Forecast: -119.2
Get CERo Therapeutics Holdings, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CERo Therapeutics Holdings, Inc. Common Stock News
New
Cero Therapeutics adds institutional investors in Series D preferred stock sale
Cero Therapeutics Holdings, Inc. (NASDAQ:CERO), currently trading at $9.63 and identified as undervalued according to InvestingPro analysis, amended its securities purchase agreement on Wednesday to i...
CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236
SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an immunotherapy company developing the next gener...
Cero Therapeutics stock rating upgraded to Buy on solid tumor approach
Investing.com - D. Boral (OTC:BOALY) Capital upgraded Cero Therapeutics (NASDAQ:CERO) from Hold to Buy on Monday, setting a price target of $30.00 based on the company’s innovative approach to T cel...
Sector Update: Health Care Stocks Retreat Late Afternoon
Health care stocks declined late Tuesday afternoon with the NYSE Health Care Index dropping 1.7% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
